GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Viemed Healthcare Inc (NAS:VMD) » Definitions » Beneish M-Score

Viemed Healthcare (Viemed Healthcare) Beneish M-Score : -1.98 (As of May. 13, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Viemed Healthcare Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.98 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Viemed Healthcare's Beneish M-Score or its related term are showing as below:

VMD' s Beneish M-Score Range Over the Past 10 Years
Min: -3.3   Med: -2.56   Max: 233.46
Current: -1.98

During the past 8 years, the highest Beneish M-Score of Viemed Healthcare was 233.46. The lowest was -3.30. And the median was -2.56.


Viemed Healthcare Beneish M-Score Historical Data

The historical data trend for Viemed Healthcare's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viemed Healthcare Beneish M-Score Chart

Viemed Healthcare Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - 233.46 -2.90 -3.21 -2.59

Viemed Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.22 -1.98 -2.26 -2.59 -1.98

Competitive Comparison of Viemed Healthcare's Beneish M-Score

For the Medical Devices subindustry, Viemed Healthcare's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viemed Healthcare's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Viemed Healthcare's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Viemed Healthcare's Beneish M-Score falls into.



Viemed Healthcare Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Viemed Healthcare for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1295+0.528 * 0.996+0.404 * 3.3675+0.892 * 1.3279+0.115 * 0.85
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9611+4.679 * -0.162705-0.327 * 1.302
=-1.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $24.5 Mil.
Revenue was 50.593 + 50.739 + 49.402 + 43.311 = $194.0 Mil.
Gross Profit was 29.802 + 32.111 + 30.562 + 26.106 = $118.6 Mil.
Total Current Assets was $38.6 Mil.
Total Assets was $154.9 Mil.
Property, Plant and Equipment(Net PPE) was $76.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $23.4 Mil.
Selling, General, & Admin. Expense(SGA) was $98.8 Mil.
Total Current Liabilities was $30.1 Mil.
Long-Term Debt & Capital Lease Obligation was $8.0 Mil.
Net Income was 1.603 + 3.477 + 2.919 + 2.33 = $10.3 Mil.
Non Operating Income was -0.146 + -0.229 + -0.008 + 0.02 = $-0.4 Mil.
Cash Flow from Operations was 1.175 + 13.284 + 13.809 + 7.623 = $35.9 Mil.
Total Receivables was $16.3 Mil.
Revenue was 39.556 + 37.508 + 35.759 + 33.31 = $146.1 Mil.
Gross Profit was 24.004 + 22.896 + 21.651 + 20.39 = $88.9 Mil.
Total Current Assets was $46.7 Mil.
Total Assets was $124.6 Mil.
Property, Plant and Equipment(Net PPE) was $68.4 Mil.
Depreciation, Depletion and Amortization(DDA) was $17.0 Mil.
Selling, General, & Admin. Expense(SGA) was $77.4 Mil.
Total Current Liabilities was $23.4 Mil.
Long-Term Debt & Capital Lease Obligation was $0.2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(24.477 / 194.045) / (16.32 / 146.133)
=0.126141 / 0.111679
=1.1295

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(88.941 / 146.133) / (118.581 / 194.045)
=0.60863 / 0.611101
=0.996

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (38.618 + 76.541) / 154.875) / (1 - (46.705 + 68.438) / 124.634)
=0.256439 / 0.076151
=3.3675

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=194.045 / 146.133
=1.3279

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(16.995 / (16.995 + 68.438)) / (23.385 / (23.385 + 76.541))
=0.198928 / 0.234023
=0.85

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(98.826 / 194.045) / (77.435 / 146.133)
=0.509294 / 0.529894
=0.9611

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((8.038 + 30.117) / 154.875) / ((0.162 + 23.421) / 124.634)
=0.24636 / 0.189218
=1.302

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(10.329 - -0.363 - 35.891) / 154.875
=-0.162705

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Viemed Healthcare has a M-score of -1.98 suggests that the company is unlikely to be a manipulator.


Viemed Healthcare Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Viemed Healthcare's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Viemed Healthcare (Viemed Healthcare) Business Description

Traded in Other Exchanges
Address
625 E. Kaliste Saloom Road, Lafayette, LA, USA, 70508
Viemed Healthcare Inc is a provider of equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services.
Executives
Jeremy Trahan officer: Chief Legal Officer 625 E. KALISTE SALOOM RD., LAFAYETTE LA 70508
Timothy Smokoff director 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508
Nitin Kaushal director 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508
Randy E. Dobbs director C/O VIEMED HEALTHCARE, INC, 625 E. KALISTE SALOOM RD, LAFAYETTE LA 70508
Bruce D Greenstein director 901 HUGH WALLIS ROAD SOUTH, LAFAYETTE LA 70508
William Todd Zehnder director, officer: Chief Operating Officer 400 E. KALISTE SALOOM ROAD, SUITE 6000, LAFAYETTE LA 70508
Casey Hoyt director, officer: Chief Executive Officer 625 E. KALISTE SALOOM RD., LAFAYETTE LA 70508
Michael Moore officer: President 625 E. KALISTE SALOOM RD., LAFAYETTE LA 70508
Trae Fitzgerald officer: Chief Financial Officer 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508
William Frazier director, officer: Chief Medical Officer 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508
Jerome Cambre officer: Vice President of Sales 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508
Sabrina Heltz director 625 E. KALISTE SALOOM ROAD, LAFAYETTE LA 70508
Ewell Patrick Eagan officer: General Counsel 625 E. KALISTE SALOOM ROAD, LAFAYETTE LA 70508